Close Menu

Editor's Pick

The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals. 

The company is creating a high-throughput NGS test for healthcare workers and the underserved, and to support viral surveillance programs for large employers.

The company saw orders for its Cologuard colorectal cancer test fall 63 percent during the first 20 days of April because of a decline in standard healthcare visits.

The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.

Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.

At the AACR annual meeting, researchers shared detection rate data for multi-cancer screening tests from Grail and Thrive Earlier Detection.

The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.

The Helsinki-based firm is making its panel available for free to people who already have been genotyped by consumer genomics services or biobanks.

The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.

A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.

Pages